Many primary-care physicians are unaware of aggressive treatment strategies that go beyond medications, the Arthritis Foundation found, despite research showing the value of support groups, exercise classes and other complementary therapies.
The arthritis drugs, those in testing and those on the market, are being showcased this week at the American College of Rheumatology meeting in San Diego, where each company is trying to show arthritis doctors why its treatment works best.
Little controlled research has been done on chondroitin sulfate, another popular arthritis treatment.
The early results of research, including one study just published and another due out soon, suggest the treatment actually does ease joint pain and may even forestall further cartilage damage.
The Food and Drug Administration said Friday it has approved meloxicam tablets for the treatment of osteoarthritis.
Vioxx has an indication for treatment of acute pain; Celebrex does not _ it has been approved for the treatment of rheumatoid arthritis and osteoarthritis.
Results showed that the drug works at least as well and probably better than other treatments for neuropathic pain, but with far fewer side effects.
Even before the NIH study is off the drawing boards, leading US arthritis specialists are recommending glucosamine to their patients _ not as a cure, but as something that reduces pain in some people and may (or may not) retard the progress of the disease, depending on whether the European study results can be confirmed.
Monsanto said most osteoarthritis patients take Celebrex once a day.
